Clearmind Medicine Inc. (CMND)
After hours:
| Previous close | 1.1800 |
| Open | 1.1800 |
| Bid | 1.1400 x 100 |
| Ask | 1.2200 x 100 |
| Day's range | 1.1300 - 1.2400 |
| 52-week range | 0.9210 - 24.6600 |
| Volume | |
| Avg. volume | 778,441 |
| Market cap | 3.865M |
| Beta (5Y monthly) | -1.69 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -30.8100 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireClearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders
Tel Aviv, Israel / Vancouver, Canada, April 17, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced an exclusive licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem. This partnership marks a significant step in harnessing generation 3.0
- GlobeNewswire
Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders
Vancouver, Canada, April 10, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "company"), a clinical- stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced that it has filed a patent application with United States Patent and Trademark Office (USPTO) for the use of 3-methylmethcathinone (with the chemical name 2-(methylamino)-1-(3-methylphenyl)-1-p
- GlobeNewswire
Clearmind Medicine CEO Issues Letter to Shareholders
Vancouver, Canada, April 09, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq:CMND), (FSE: CWY0) (“Clearmind” or the “company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today provided the following letter to shareholders from the Company’s CEO, Dr. Adi Zuloff-Shani: “In 2023, Clearmind made significant advances on its groundbreaking journey, propelling our flagship compou
